Rockefeller Capital Management L.P. acquired a new position in Immuneering Co. (NASDAQ:IMRX - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 177,377 shares of the company's stock, valued at approximately $390,000. Rockefeller Capital Management L.P. owned about 0.57% of Immuneering at the end of the most recent quarter.
Separately, HighTower Advisors LLC increased its holdings in Immuneering by 21.4% in the 3rd quarter. HighTower Advisors LLC now owns 53,360 shares of the company's stock worth $132,000 after acquiring an additional 9,400 shares during the last quarter. 67.65% of the stock is owned by institutional investors.
Immuneering Price Performance
Shares of IMRX traded up $0.01 during midday trading on Tuesday, hitting $1.46. 11,230 shares of the company traded hands, compared to its average volume of 2,335,171. The stock has a 50-day moving average of $1.50 and a 200-day moving average of $1.84. Immuneering Co. has a one year low of $1.00 and a one year high of $3.83. The firm has a market cap of $52.54 million, a P/E ratio of -0.74 and a beta of -0.25.
Immuneering (NASDAQ:IMRX - Get Free Report) last posted its earnings results on Thursday, March 20th. The company reported ($0.58) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.42) by ($0.16). Sell-side analysts forecast that Immuneering Co. will post -1.86 EPS for the current fiscal year.
Wall Street Analyst Weigh In
A number of equities analysts have weighed in on IMRX shares. Needham & Company LLC reiterated a "buy" rating and set a $12.00 target price on shares of Immuneering in a research report on Thursday, April 10th. Chardan Capital reiterated a "buy" rating and issued a $13.00 price objective on shares of Immuneering in a research note on Monday, March 24th.
View Our Latest Research Report on IMRX
About Immuneering
(
Free Report)
Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors.
Featured Stories
Before you consider Immuneering, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Immuneering wasn't on the list.
While Immuneering currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
